Abstract
Wegener granulomatosis (WG) is a systemic vasculitis of small and medium vessels. It predominantly affects the upper and/or lower respiratory airway and kidneys. Its pathogenesis is not fully understood. WG relatively frequently affects the nervous system (in 30–50% according to the different studies). Most frequently, it manifests as necrotizing vasculitis that leads to the peripheral neuropathies or to the cranial nerves palsy. Impairment of the central nervous system (CNS) is less frequent and occurs in 2–8% of patients. Three major pathogenetic mechanisms were described: CNS vasculitis, spreading of granulomas from the adjacent anatomical areas (paranasal cavities, orbit etc.), and new formation of granulomas in brain tissue. This case report describes patients in whom WG manifested in the form of localized skin involvement and combined CNS involvement that included pituitary gland. Atypical presentation of WG impedes and slows down the process of diagnosis and emphasizes the need for collaboration between medical specialists.
References
Bartunkova J, Tesar V, Sediva A (2003) Diagnostic and pathogenetic role of antineutrophil cytoplasmic autoantibodies. Clin Immunol 106:73–82
Fauci AS, Haynes BF, Katz P, Wolff SM (1983) Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 98:76–85
Matteson EL, Gold KN, Bloch DA, Hunder GG (1996) Long-term survival of patients with Wegener's granulomatosis from the American College of Rheumatology Wegener's granulomatosis classification criteria cohort. Am J Med 101:129–134
Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH et al (2003) Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 41:776–784
Nishino H, Rubino FA, DeRemee RA, Swanson JW, Parisi JE (1993) Neurological involvement in Wegener's granulomatosis: an analysis of 324 consecutive patients at the Mayo Clinic. Ann Neurol 33:4–9
Nishino H, Rubino FA, Parisi JE (1993) The spectrum of neurologic involvement in Wegener's granulomatosis. Neurology 43:1334–1337
Murphy JM, Gomez-Anson B, Gillard JH, Antoun NM, Cross J, Elliott JD et al (1999) Wegener granulomatosis: MR imaging findings in brain and meninges. Radiology 213:794–799
Miller KS, Miller JM (1993) Wegener's granulomatosis presenting as a primary seizure disorder with brain lesions demonstrated by magnetic resonance imaging. Chest 103:316–318
Oimomi M, Suehiro I, Mizuno N, Baba S, Okada S, Kanazawa Y (1980) Wegener's granulomatosis with intracerebral granuloma and mammary manifestation. Report of a case. Arch Intern Med 140:853–854
Miesen WM, Janssens EN, van Bommel EF (1999) Diabetes insipidus as the presenting symptom of Wegener's granulomatosis. Nephrol Dial Transplant 14:426–429
Katzman GL, Langford CA, Sneller MC, Koby M, Patronas NJ (1999) Pituitary involvement by Wegener's granulomatosis: a report of two cases. AJNR Am J Neuroradiol 20:519–523
Provenzale JM, Allen NB (1996) Wegener granulomatosis: CT and MR findings. AJNR Am J Neuroradiol 17:785–792
Haynes BF, Fauci AS (1978) Diabetes insipidus associated with Wegener's granulomatosis successfully treated with cyclophosphamide. N Engl J Med 299:764
Hurst NP, Dunn NA, Chalmers TM (1983) Wegener's granulomatosis complicated by diabetes insipidus. Ann Rheum Dis 42:600–601
Garovic VD, Clarke BL, Chilson TS, Specks U (2001) Diabetes insipidus and anterior pituitary insufficiency as presenting features of Wegener's granulomatosis. Am J Kidney Dis 37:E5
Acknowledgement
This work was supported by the grant MSM 0021620812 provided by the Ministry of Education.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Špíšek, R., Kolouchová, E., Jenšovský, J. et al. Combined CNS and pituitary involvement as a primary manifestation of Wegener granulomatosis. Clin Rheumatol 25, 739–742 (2006). https://doi.org/10.1007/s10067-005-0065-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-005-0065-5